{
    "root": "242bb74c-354e-4c6c-8b0b-cf653cb62e0e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Xacduro",
    "value": "20250327",
    "ingredients": [],
    "indications": "xacduro co-packaged product containing sulbactam , beta-lactam antibacterial beta lactamase inhibitor , durlobactam , beta lactamase inhibitor , indicated patients 18 years age older treatment hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia ( habp/vabp ) , caused susceptible isolates acinetobacter baumannii-calcoaceticus complex . ( 1.1 ) limitations : xacduro indicated treatment habp/vabp caused pathogens susceptible isolates acinetobacter baumannii-calcoaceticus complex . ( 1.1 , 14 ) reduce development drug-resistant bacteria maintain effectiveness xacduro antibacterial drugs , xacduro used treat prevent infections proven strongly suspected caused bacteria . ( 1.2 )",
    "contraindications": "administer xacduro ( 1 g sulbactam , 1 g durlobactam ) every 6 hours intravenous ( iv ) infusion 3 hours patients creatinine clearance ( clcr ) 45 129 ml/min . ( 2.1 ) dosing regimen adjustments recommended clcr less 45 ml/min clcr greater equal 130 ml/min . ( 2.2 ) administer doses xacduro iv infusion 3 hours . ( 2.3 ) full prescribing information instructions preparation intravenous solution . ( 2.4 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "xacduro contraindicated patients history known severe hypersensitivity components xacduro ( sulbactam durlobactam ) , beta-lactam antibacterial drugs [ ( 5.1 ) ] .",
    "indications_original": "XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 ) Limitations of Use : XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. ( 1.1 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 )",
    "contraindications_original": "Administer XACDURO (1 g of sulbactam, 1 g of durlobactam) every 6 hours by intravenous (IV) infusion over 3 hours in patients with creatinine clearance (CLcr) of 45 to 129 mL/min. ( 2.1 ) Dosing regimen adjustments are recommended for CLcr less than 45 mL/min and CLcr greater than or equal to 130 mL/min. ( 2.2 ) Administer all doses of XACDURO by IV infusion over 3 hours. ( 2.3 ) See full prescribing information for instructions on the preparation of the intravenous solution. ( 2.4 )",
    "adverseReactions_original": "XACDURO is contraindicated in patients with a history of known severe hypersensitivity to the components of XACDURO (sulbactam and durlobactam), or other beta-lactam antibacterial drugs [see Warnings and Precautions (5.1)]."
}